Compare · APEN vs STE
APEN vs STE
Side-by-side comparison of Apollo Endosurgery Inc. (APEN) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APEN and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.73B, about 103.1x APEN ($201.0M).
- STE has hit the wire 32 times in the past 4 weeks while APEN has been quiet.
- STE has more recent analyst coverage (16 ratings vs 6 for APEN).
- Company
- Apollo Endosurgery Inc.
- STERIS plc (Ireland)
- Price
- $9.99+0.71%
- $212.19-0.03%
- Market cap
- $201.0M
- $20.73B
- 1M return
- -
- -1.07%
- 1Y return
- -
- -12.59%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 32
- Recent ratings
- 6
- 16
Apollo Endosurgery Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest APEN
- SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)
- SEC Form 15-12G filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
- SEC Form EFFECT filed by Apollo Endosurgery Inc.
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 184 units of Ordinary Shares, decreasing direct ownership by 2% to 11,482 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 311 units of Ordinary Shares, decreasing direct ownership by 2% to 14,316 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 2,619 units of Ordinary Shares, decreasing direct ownership by 4% to 69,964 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 190 units of Ordinary Shares, decreasing direct ownership by 1% to 13,274 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam was granted 4,359 units of Ordinary Shares and covered exercise/tax liability with 247 units of Ordinary Shares, increasing direct ownership by 12% to 37,444 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato was granted 750 units of Ordinary Shares and covered exercise/tax liability with 41 units of Ordinary Shares, increasing direct ownership by 13% to 6,323 units (SEC Form 4)